XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Condensed Balance Sheets - USD ($)
$ in Thousands
Apr. 01, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 47,102 $ 30,186
Accounts receivable, net 118,544 136,295
Inventory 87,953 84,766
Prepaid and other current assets 17,192 18,551
Assets held for sale 37,873 0
Current assets attributable to discontinued operations 0 2,777
Total current assets 308,664 272,575
Property and equipment, net 36,556 27,456
Goodwill 7,462 7,462
Intangible assets, net 516,039 639,851
Operating lease assets 16,063 16,690
Investment and other assets 2,620 2,621
Long-term assets attributable to discontinued operations 0 405,994
Total assets 887,404 1,372,649
Current liabilities:    
Accounts payable 32,828 36,697
Accrued liabilities 115,769 111,570
Current portion of long-term debt 41,320 33,056
Other current liabilities 4,273 3,607
Liabilities held for sale 1,873 0
Current liabilities attributable to discontinued operations 0 119,087
Total current liabilities 196,063 304,017
Long-term debt, less current portion 404,265 385,010
Deferred income taxes 351 2,248
Contingent consideration 17,718 17,431
Other long-term liabilities 28,645 22,810
Long-term liabilities attributable to discontinued operations 0 228,911
Total liabilities 647,042 960,427
Commitments and contingencies (Note 11)
Stockholders’ Equity    
Additional paid-in capital 492,475 490,576
Accumulated deficit (304,456) (165,306)
Accumulated other comprehensive income (loss) 413 (110)
Total stockholders’ equity attributable to Bioventus Inc. 188,511 325,238
Noncontrolling interest 51,851 86,984
Total stockholders’ equity 240,362 412,222
Total liabilities and stockholders’ equity 887,404 1,372,649
Common Class A    
Stockholders’ Equity    
Common stock, value 63 62
Common Class B    
Stockholders’ Equity    
Common stock, value $ 16 $ 16